结核病诊断市场－全球产业规模、份额、趋势、机会和预测，按检测类型、最终用途、地区和竞争格局划分，2020-2030年预测

2024年全球结核病诊断市场规模为25.2亿美元，预计2030年将以6.37%的复合年增长率成长至36.5亿美元。全球结核病诊断市场致力于开发和应用用于识别结核分枝桿菌（结核病的病原体）的检测方法和工具。全球结核病负担沉重，以及对快速、精准检测的迫切需求，是推动市场扩张的主要因素。技术进步，特别是分子检测技术的进步，以及政府和组织对结核病防治日益增长的支持，进一步促进了市场成长。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球结核病诊断市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依检测类型（放射线照相法、诊断实验室方法、核酸检测、噬菌体检测、潜伏感染检测、细胞激素检测、药物抗药性检测（DST）等）
  • 依最终用途（诊断实验室、医院和诊所、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美结核病诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲结核病诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区结核病诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲结核病诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲结核病诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球结核病诊断市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Abbott Laboratories Inc.
• Becton, Dickinson, and Company
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• BioMerieux SA
• Hain Lifescience GmbH
• QIAGEN NV
• Cepheid
• Hologic, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Tuberculosis Diagnostics Market, valued at USD 2.52 Billion in 2024, is projected to experience a CAGR of 6.37% to reach USD 3.65 Billion by 2030. The global tuberculosis diagnostics market develops and deploys tests and tools for identifying *Mycobacterium tuberculosis*, the causative agent of tuberculosis. Market expansion is driven by the significant global disease burden and the imperative for swift, precise detection. Technological advancements, particularly in molecular assays, alongside increasing governmental and organizational support for TB control, further stimulate growth.

Key Market Drivers

The advancements in diagnostic technologies significantly propel the global tuberculosis diagnostics market by enhancing the speed, accuracy, and accessibility of testing solutions. Innovations such as molecular diagnostics, artificial intelligence powered imaging, and next-generation sequencing are transforming the diagnostic landscape, enabling earlier detection and more effective disease management. These technological improvements are particularly crucial for identifying latent tuberculosis infection and for deployment in diverse healthcare settings, from central laboratories to point-of-care environments. For instance, according to a Pharmacy Times news report, in April 2025, the FDA approved the Auto-Pure 2400 liquid handling platform with the T-SPOT. TB test, which allows laboratories to process up to 24 samples in under 3.5 hours for faster and more accurate latent TB diagnosis.

Key Market Challenges

Ensuring affordable and accessible advanced diagnostic technologies in resource-limited regions presents a significant impediment to the expansion of the Global Tuberculosis Diagnostics Market. The high capital expenditure required for advanced molecular diagnostic platforms, coupled with the recurring costs of reagents and consumables, creates substantial financial barriers for public health systems in high-burden, low-income countries. This economic constraint often leads to the underutilization or non-adoption of advanced diagnostic tools despite their accuracy and speed.

Key Market Trends

The rise in automated diagnostic platforms significantly drives the global tuberculosis diagnostics market by enhancing testing throughput and operational efficiency. These systems streamline laboratory workflows, minimizing manual intervention and accelerating sample processing, thereby reducing turnaround times for results. By the end of 2023, the Stop TB Partnership reported that cumulative global procurement of GeneXpert machines, representing key automated molecular platforms, exceeded 16,000 units across 167 countries, demonstrating substantial integration into diagnostic infrastructure. This increased capacity is crucial for managing high sample volumes in high-burden settings.

Key Market Players

• Abbott Laboratories Inc.
• Becton, Dickinson, and Company
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• BioMerieux SA
• Hain Lifescience GmbH
• QIAGEN NV
• Cepheid
• Hologic, Inc.

Report Scope:

In this report, the Global Tuberculosis Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tuberculosis Diagnostics Market, By Test Type:

• Radiographic Method
• Diagnostic Laboratory Methods
• Nucleic Acid Testing
• Phage Assay
• Detection of Latent Infection
• Cytokine Detection Assay
• Detection of Drug Resistance (DST)
• Others

Tuberculosis Diagnostics Market, By End-Use:

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

Tuberculosis Diagnostics Market, By Region:

• North America
• Europe
• Asia-Pacific
• South America
• MEA

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tuberculosis Diagnostics Market.

Available Customizations:

Global Tuberculosis Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tuberculosis Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Test Type (Radiographic Method, Diagnostic Laboratory Methods, Nucleic Acid Testing, Phage Assay, Detection of Latent Infection, Cytokine Detection Assay, Detection of Drug Resistance (DST), others)
  • 5.2.2. By End-Use (Diagnostic Laboratories, Hospitals & Clinics, others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Tuberculosis Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Test Type
  • 6.2.2. By End-Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tuberculosis Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Test Type
      • 6.3.1.2.2. By End-Use
  • 6.3.2. Canada Tuberculosis Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Test Type
      • 6.3.2.2.2. By End-Use
  • 6.3.3. Mexico Tuberculosis Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Test Type
      • 6.3.3.2.2. By End-Use

7. Europe Tuberculosis Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test Type
  • 7.2.2. By End-Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tuberculosis Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Test Type
      • 7.3.1.2.2. By End-Use
  • 7.3.2. France Tuberculosis Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Test Type
      • 7.3.2.2.2. By End-Use
  • 7.3.3. United Kingdom Tuberculosis Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Test Type
      • 7.3.3.2.2. By End-Use
  • 7.3.4. Italy Tuberculosis Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Test Type
      • 7.3.4.2.2. By End-Use
  • 7.3.5. Spain Tuberculosis Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Test Type
      • 7.3.5.2.2. By End-Use

8. Asia Pacific Tuberculosis Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Test Type
  • 8.2.2. By End-Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tuberculosis Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Test Type
      • 8.3.1.2.2. By End-Use
  • 8.3.2. India Tuberculosis Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Test Type
      • 8.3.2.2.2. By End-Use
  • 8.3.3. Japan Tuberculosis Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Test Type
      • 8.3.3.2.2. By End-Use
  • 8.3.4. South Korea Tuberculosis Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Test Type
      • 8.3.4.2.2. By End-Use
  • 8.3.5. Australia Tuberculosis Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Test Type
      • 8.3.5.2.2. By End-Use

9. Middle East & Africa Tuberculosis Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Test Type
  • 9.2.2. By End-Use
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tuberculosis Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Test Type
      • 9.3.1.2.2. By End-Use
  • 9.3.2. UAE Tuberculosis Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Test Type
      • 9.3.2.2.2. By End-Use
  • 9.3.3. South Africa Tuberculosis Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Test Type
      • 9.3.3.2.2. By End-Use

10. South America Tuberculosis Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Test Type
  • 10.2.2. By End-Use
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tuberculosis Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Test Type
      • 10.3.1.2.2. By End-Use
  • 10.3.2. Colombia Tuberculosis Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Test Type
      • 10.3.2.2.2. By End-Use
  • 10.3.3. Argentina Tuberculosis Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Test Type
      • 10.3.3.2.2. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tuberculosis Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson, and Company
• 15.3. F. Hoffmann-La Roche Ltd.
• 15.4. Thermo Fisher Scientific Inc.
• 15.5. BioMerieux SA
• 15.6. Hain Lifescience GmbH
• 15.7. QIAGEN NV
• 15.8. Cepheid
• 15.9. Hologic, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer